Human LDL

Low-density lipoproteins pre-screened for hematopoietic cell growth

More Views

Human LDL

Low-density lipoproteins pre-screened for hematopoietic cell growth

5 mg
Catalog #02698
411 USD

Overview

This product is a human plasma-derived low-density lipoprotein (LDL)-based culture supplement that has been pre-screened for the culture, expansion, and colony assay of human hematopoietic and non-hematopoietic cells in serum-free culture media. It promotes the proliferation and survival of human hematopoietic and other progenitor cells in culture, resulting in increased cell output in expansion cultures and increased colony numbers and/or size in colony assays.
Contains:
• A clear micro-emulsion of low-density lipoproteins in an aqueous solution
• 5 mg/mL protein as determined by modified Lowry Method using bovine serum albumin as a standard
Subtype:
Supplements
Cell Type:
Hematopoietic Stem and Progenitor Cells; Other
Species:
Human
Application:
Cell Culture

Scientific Resources

Product Documentation

Document Type
Product Name
Catalog #
Lot #
Language

Educational Materials

(1)

Product Applications

This product is designed for use in the following research area(s) as part of the highlighted workflow stage(s). Explore these workflows to learn more about the other products we offer to support each research area.

Data and Publications

Data

Importance of Low Density Lipoproteins

Figure 1. Importance of Low Density Lipoproteins

Effect of low density lipoproteins (LDLs) on megakaryocyte expansion in StemSpan™ H3000 supplemented with StemSpan™ Megakaryocyte Expansion Supplement

Publications

(2)
Cell stem cell 2019 mar

The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance.

N. Vannini et al.

Abstract

It has been recently shown that increased oxidative phosphorylation, as reflected by increased mitochondrial activity, together with impairment of the mitochondrial stress response, can severely compromise hematopoietic stem cell (HSC) regeneration. Here we show that the NAD+-boosting agent nicotinamide riboside (NR) reduces mitochondrial activity within HSCs through increased mitochondrial clearance, leading to increased asymmetric HSC divisions. NR dietary supplementation results in a significantly enlarged pool of progenitors, without concurrent HSC exhaustion, improves survival by 80{\%}, and accelerates blood recovery after murine lethal irradiation and limiting-HSC transplantation. In immune-deficient mice, NR increased the production of human leucocytes from hCD34+ progenitors. Our work demonstrates for the first time a positive effect of NAD+-boosting strategies on the most primitive blood stem cells, establishing a link between HSC mitochondrial stress, mitophagy, and stem-cell fate decision, and unveiling the potential of NR to improve recovery of patients suffering from hematological failure including post chemo- and radiotherapy.
Nature methods 2017 JUN

Marker-free coselection for CRISPR-driven genome editing in human cells.

D. Agudelo et al.

Abstract

Targeted genome editing enables the creation of bona fide cellular models for biological research and may be applied to human cell-based therapies. Therefore, broadly applicable and versatile methods for increasing its efficacy in cell populations are highly desirable. We designed a simple and robust coselection strategy for enrichment of cells with either nuclease-driven nonhomologous end joining (NHEJ) or homology-directed repair (HDR) events by harnessing the multiplexing capabilities of CRISPR-Cas9 and Cpf1 systems. Selection for dominant alleles of the ubiquitous sodium/potassium pump (Na+/K+ ATPase) that rendered cells resistant to ouabain was used to enrich for custom genetic modifications at another unlinked locus of interest, thereby effectively increasing the recovery of engineered cells. The process is readily adaptable to transformed and primary cells, including hematopoietic stem and progenitor cells. The use of universal CRISPR reagents and a commercially available small-molecule inhibitor streamlines the incorporation of marker-free genetic changes in human cells.
STEMCELL TECHNOLOGIES INC.’S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.